Format

Send to

Choose Destination
Am J Transplant. 2017 Apr;17(4):901-911. doi: 10.1111/ajt.14173. Epub 2017 Feb 2.

Integrating APOL1 Gene Variants Into Renal Transplantation: Considerations Arising From the American Society of Transplantation Expert Conference.

Author information

1
Department of Surgery, Emory University School of Medicine, Atlanta, GA.
2
Department of Medicine, Yale University School of Medicine, New Haven, CN.
3
Division of Nephrology, Centre for Health Evaluation and Outcomes Sciences, University of British Columbia, Vancouver, Canada.
4
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.
5
Department of Surgery, Massachusetts General Hospital, Harvard University, Boston, MA.
6
American Society of Transplantation, Mt. Laurel, NJ.
7
University of Colorado, Denver, CO.
8
Schuster Family Transplantation Research Center, Renal Division, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.

Abstract

Thirteen percent of individuals of African ancestry express two variant copies of the gene encoding apolipoprotein 1 (APOL1) that has been associated with an increased risk of end-stage renal disease (ESRD) in the general population. Limited studies suggest that the survival of transplanted kidneys from donors expressing two APOL1 risk alleles is inferior to that of kidneys from donors with zero or one risk allele. In living kidney donation, two case reports describe donors expressing two APOL1 risk alleles who developed ESRD. Given the potential impact of APOL1 variants on the utility and safety of kidney transplantation and living kidney donation, the American Society of Transplantation convened a meeting with the goals of summarizing the current state of knowledge with respect to transplantation and APOL1, identifying knowledge gaps and studies to address these gaps, and considering approaches to integrating APOL1 into clinical practice. The authors recognize that current data are not sufficient to support traditional evidence-based guidelines but also recognize that it may require several years to generate the necessary data. Thus, approaches as to how APOL1 might currently be integrated into the clinical decision-making process were considered. This report summarizes the group's deliberations.

KEYWORDS:

clinical research/practice; disparities; donors and donation; ethics and public policy; genetics; graft survival; kidney disease; kidney transplantation/nephrology

PMID:
27997071
DOI:
10.1111/ajt.14173
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center